文献速递肺外科

肺结外边缘区B细胞淋巴瘤的治疗结局

Treatment outcomes in patients with extranodal marginal zone B-cell lymphoma of the lung.
PubMed 文献 · J Thorac Cardiovasc Surg · 2017-03-21

该回顾性研究纳入2003年至2015年诊断的51例肺黏膜相关淋巴组织(MALT)淋巴瘤患者,按改良Ann Arbor分期分为低分期(IE/IIE)和高分期(IIIE/IVE)组,比较治疗方式与结局。低分期患者以手术切除为主,高分期以化疗为主;中位随访40.7个月,低分期无进展生存期更长,高分期进展风险显著增高(HR 9.24,95%CI 1.93-44.36)。

要点

  • 低分期肺MALT淋巴瘤以手术切除为主,临床病程可能惰性。
  • 高分期患者进展风险显著高于低分期(HR 9.24,95%CI 1.93-44.36)。
  • 低分期患者中位无进展生存期40.7个月,高分期24.9个月(P < .001)。

核心结论

  • 低分期肺MALT淋巴瘤以手术切除为主要治疗方式,临床病程可能惰性。

主要发现

  • 76.5%(39/51)患者为IE期;随分期进展,呼吸系统症状、B症状和更高国际预后指数评分更常见。
  • 低分期患者最常见治疗为手术切除(33/43),高分期最常见为化疗(7/8)。
  • 中位随访40.7个月,低分期无进展生存期更长(中位40.7个月 vs 24.9个月;P < .001)。
  • 高分期患者进展风险为低分期的9.2倍(HR 9.24;95%CI 1.93-44.36)。
  • 30例手术切除的IE期患者中,8例中央型病灶行肺叶切除,22例外周型病灶行肺叶切除(n=8)或局限切除(n=14);1例中央型病灶患者出现复发。

临床怎么用

  • 对于低分期肺MALT淋巴瘤,手术切除可作为主要治疗选择。
  • 高分期患者进展风险高,需更密切随访并考虑全身治疗。

局限性

  • 回顾性研究,样本量较小(51例),高分期患者仅8例。
  • 单中心经验,治疗选择可能存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate clinical presentations, treatment modalities, and outcomes of pulmonary mucosa-associated lymphoid tissue (MALT) lymphoma by stage strata. METHODS: We retrospectively reviewed 51 patients diagnosed with pulmonary MALT lymphoma between January 2003 and December 2015. To compare treatment modalities and outcomes, we stratified the patients into low-stage (IE/IIE) and high-stage (IIIE/IVE) groups using modified Ann Arbor staging. Progression-free survival was estimated using Kaplan-Meier curves, and differences were compared using the log-rank test. A hazard ratio of progression by stage strata, adjusted for other clinical variables, was determined using a Cox adjusted proportional hazards model. RESULTS: The majority of patients had stage IE disease (76.5%; 39 of 51). With advancing stage, patients were more likely to have respiratory and B symptoms and higher International Prognostic Index scores. The most common treatment modality was surgical resection in low-stage patients (33 of 43) and chemotherapy in high-stage patients (7 of 8). At a median follow-up of 40.7 months, progression-free survival was longer for low-stage patients (median, 40.7 months vs 24.9 months; P < .001), and high-stage patients were 9.2 times more likely to progress (hazard ratio, 9.24; 95% confidence interval, 1.93-44.36). Among 30 patients with surgically resected stage IE disease, 8 with central lesions were treated via lobectomy and 22 with peripheral lesions were treated via lobectomy (n = 8) or limited resection (n = 14). One of these patients, with a central lesion, experienced disease recurrence. CONCLUSIONS: Our findings suggest that the clinical course of low-stage pulmonary MALT lymphoma, for which the mainstay of treatment is surgical resection, might be indolent.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Lee H, Yang B, Nam B, et al. Treatment outcomes in patients with extranodal marginal zone B-cell lymphoma of the lung. J Thorac Cardiovasc Surg. 2017. PMID: 28457544. doi:10.1016/j.jtcvs.2017.03.043

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。